Madrigal Pharmaceuticals (MDGL) News Today $344.02 -2.38 (-0.69%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Knights of Columbus Asset Advisors LLC Buys 2,116 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Knights of Columbus Asset Advisors LLC grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 82.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,695 shares oMarch 24 at 5:49 AM | marketbeat.comCibc World Markets Corp Makes New $519,000 Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Cibc World Markets Corp purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,681 shares of the biopharmaceuticaMarch 23 at 3:52 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating,March 23 at 2:35 AM | marketbeat.comMadrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comWilliam Blair Investment Management LLC Purchases Shares of 371,771 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)William Blair Investment Management LLC purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 371,771 shares of the biopharmaMarch 18, 2025 | marketbeat.comRaymond James Financial Inc. Takes $16.62 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Raymond James Financial Inc. acquired a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 53,846 shares oMarch 18, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $2.43 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Skandinaviska Enskilda Banken AB publ lowered its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,798 shares of the bMarch 17, 2025 | marketbeat.comProficio Capital Partners LLC Acquires New Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Proficio Capital Partners LLC acquired a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 17,280 shares of the biopharmaceutical company's stock, valued atMarch 17, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $46.52 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Charles Schwab Investment Management Inc. boosted its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 1.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 150,746 shares of the biopharmaceutical company's stock after purchasing an additMarch 15, 2025 | marketbeat.comMadrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potentialMarch 14, 2025 | investing.comWintrust Investments LLC Purchases 900 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Wintrust Investments LLC grew its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 86.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,937 shares of the biopharmaMarch 14, 2025 | marketbeat.comMadrigal Pharmaceuticals Announces Changes to Board of DirectorsMarch 13, 2025 | msn.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Erste Asset Management GmbHErste Asset Management GmbH lessened its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 29.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 164,400 shares of the biopharmaceutical company's stock after selling 70,000 sharesMarch 13, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 43.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 103,288 shares of the biopMarch 13, 2025 | marketbeat.comMadrigal Pharmaceuticals management to meet with OppenheimerMarch 13, 2025 | markets.businessinsider.comDorsey & Whitney Trust CO LLC Makes New $257,000 Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Dorsey & Whitney Trust CO LLC acquired a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 834 shares of the biopharmaceutical company's stock, valueMarch 12, 2025 | marketbeat.comVictory Capital Management Inc. Has $21.80 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Victory Capital Management Inc. boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 2,981.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,635 shaMarch 12, 2025 | marketbeat.comMadrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of DirectorsMarch 11, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals appoints Fouse to its board of directorsMarch 11, 2025 | markets.businessinsider.comMadrigal Appoints Jacqualyn A. Fouse, Ph.D.March 11, 2025 | globenewswire.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 14,113 SharesMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 14,113 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total transaction of $4,817,049.16. Following the completion of the sale, the vice president now directly owns 3,728 shares of the company's stock, valued at approximately $1,272,440.96. This represents a 79.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 8, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells $4,817,049.16 in StockMarch 8, 2025 | insidertrades.comAigen Investment Management LP Purchases New Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Aigen Investment Management LP bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,771 shares of the biopharmaceutical company's stock, vMarch 7, 2025 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)March 6, 2025 | markets.businessinsider.comInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 1,227 Shares of StockMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 1,227 shares of the business's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $341.07, for a total transaction of $418,492.89. Following the completion of the sale, the vice president now owns 3,728 shares in the company, valued at $1,271,508.96. This represents a 24.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.March 6, 2025 | marketbeat.comCarrera Capital Advisors Purchases New Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Carrera Capital Advisors acquired a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,243 shares of the biopharmaceutical comMarch 5, 2025 | marketbeat.comRobert E. Waltermire Sells 1,227 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) StockMarch 5, 2025 | insidertrades.comProficio Capital Partners LLC Takes $5.33 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Proficio Capital Partners LLC purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 17,280 shares of the biopharmaceutical company's stock, valued at approximMarch 4, 2025 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% Following Insider SellingMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 6.8% Following Insider SellingMarch 3, 2025 | marketbeat.comLos Angeles Capital Management LLC Purchases Shares of 2,752 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Los Angeles Capital Management LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,752 shares of the biopharmaceutical company'March 3, 2025 | marketbeat.comBrokers Set Expectations for MDGL Q2 EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Madrigal Pharmaceuticals in a report released on Wednesday, February 26th. Leerink Partnrs analyst T. Smith expects that the biopharmaceuticaMarch 3, 2025 | marketbeat.comB. Riley Analysts Increase Earnings Estimates for MDGLMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities researchers at B. Riley raised their Q1 2025 EPS estimates for Madrigal Pharmaceuticals in a research note issued on Thursday, February 27th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will posMarch 3, 2025 | marketbeat.comHC Wainwright Issues Negative Estimate for MDGL EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Investment analysts at HC Wainwright decreased their Q1 2025 earnings estimates for Madrigal Pharmaceuticals in a report issued on Thursday, February 27th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company wMarch 3, 2025 | marketbeat.comInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 15,470 Shares of StockMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director James M. Daly sold 15,470 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $347.45, for a total value of $5,375,051.50. Following the completion of the sale, the director now directly owns 1,912 shares of the company's stock, valued at approximately $664,324.40. This represents a 89.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 2, 2025 | marketbeat.comJames M. Daly Sells 15,470 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) StockMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director James M. Daly sold 15,470 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $347.45, for a total value of $5,375,051.50. Following the completion of the transaction, the director now owns 1,912 shares in the company, valued at approximately $664,324.40. The trade was a 89.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 1, 2025 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded at B. RileyB. Riley raised Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday.March 1, 2025 | marketbeat.comCitigroup Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock PriceCitigroup increased their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a report on Thursday.February 28, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $405.00 at HC WainwrightHC Wainwright increased their price target on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a "buy" rating in a research note on Thursday.February 28, 2025 | marketbeat.comMadrigal Pharmaceuticals price target raised to $469 from $378 at CitiFebruary 27, 2025 | markets.businessinsider.comDecoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture?February 27, 2025 | benzinga.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Announces Quarterly Earnings ResultsMadrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, topping the consensus estimate of ($4.32) by $1.61.February 27, 2025 | marketbeat.comWe're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash BurnFebruary 27, 2025 | finance.yahoo.comMadrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...February 27, 2025 | finance.yahoo.comMadrigal Pharmaceuticals upgraded to Buy from Neutral at B. RileyFebruary 27, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals price target raised to $239 from $154 at BofAFebruary 27, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 12-Month High Following Earnings BeatMadrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 12-Month High on Earnings BeatFebruary 27, 2025 | marketbeat.comMadrigal Pharma stock jumps on positive trial results and revenue beatFebruary 27, 2025 | investing.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock, Short Interest ReportFebruary 27, 2025 | benzinga.comMadrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBSFebruary 27, 2025 | markets.businessinsider.com Remove Ads Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Media Mentions By Week MDGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDGL News Sentiment▼1.570.63▲Average Medical News Sentiment MDGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDGL Articles This Week▼57▲MDGL Articles Average Week Remove Ads Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News Today United Therapeutics News Today BioMarin Pharmaceutical News Today Incyte News Today Neurocrine Biosciences News Today Exelixis News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Alkermes News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDGL) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MDGL Stock Free MDGL Stock Alerts